Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceed will be used in the clinical development of Cytisinicline, which is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor and will using for Smoking Cessation in adult smokers.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Propel Bio Partners LLC
Deal Size: $124.2 million Upfront Cash: $60.0 million
Deal Type: Private Placement February 29, 2024
Details:
Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is being evaluated for the treatment of smoking cessation and nicotine dependence.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
The proceeds will fund product development, including cytisinicline, a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor believed to aid in treating nicotine addiction for smoking and e-cigarette cessation.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lake Street Capital
Deal Size: $16.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 25, 2023
Details:
Cytisine (cytisiniclin)e is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
Cytisine (cytisiniclin)e is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal symptoms.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Achieve continues to pursue numerous patents that will further enhance the product’s stability and the potential for life cycle.
Lead Product(s): Cytisine
Therapeutic Area: Psychiatry/Psychology Product Name: Cytisine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022